A Three-Year Follow-Up of Bone Density Among Thai Adolescents With Perinatally Acquired HIV After Completion of Vitamin D and Calcium Supplementation

J Adolesc Health. 2023 Aug;73(2):262-270. doi: 10.1016/j.jadohealth.2023.03.012. Epub 2023 Jun 7.

Abstract

Purpose: To determine changes in bone mineral density (BMD) and bone metabolism-related biomarkers among Thai adolescents with perinatally acquired HIV infection (PHIVA) at 3 years following completion of vitamin D and calcium (VitD/Cal) supplementation.

Methods: An observational follow-up study was conducted among PHIVA who received 48-week VitD/Cal supplementation (either high-dose [3,200 IU/1,200 mg daily] or standard-dose [400 IU/1,200 mg daily]). Lumbar spine BMD (LSBMD) was assessed by dual-energy x-ray absorptiometry. Serum 25-hydroxyvitamin D, intact parathyroid hormone, and bone turnover markers were measured. Changes in LSBMD z-scores and other bone parameters at 3 years after stopping VitD/Cal supplementation compared with baseline or week 48 of supplementation were assessed among participants previously receiving high-dose and standard-dose VitD/Cal supplementation.

Results: Of 114 enrolled PHIVA, 46% and 54% had previously received high-dose and standard-dose VitD/Cal supplementation, respectively. The median age was 20 years; 53% were male. At 3 years after completion of VitD/Cal supplementation, we observed a significant decline in 25-hydroxyvitamin D and increase in intact parathyroid hormone but no significant rebounds of C-terminal telopeptides of collagen type I and procollagen type I amino-terminal propeptides and no significant changes in LSBMD z-scores among PHIVA in both treatment groups, compared with the measurements at week 48 of supplementation. Notably, LSBMD z-scores at 3 years after stopping VitD/Cal supplements were not significantly altered from baseline evaluations in both PHIVA groups.

Discussion: Three years after completion of high-dose or standard-dose VitD/Cal supplementation, LSBMD z-scores of our Thai PHIVA were not significantly changed from baseline and week 48 of supplementation. VitD/Cal supplementation of PHIVA during periods of peak bone mass accrual may have sustained and long-term skeletal benefits.

Keywords: Bone density; Bone health; Bone mass; HIV-infected adolescents; HIV-infected youth; Long-term follow-up; Perinatally acquired HIV infection; Youth living with HIV.

Publication types

  • Observational Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Bone Density*
  • Calcium / therapeutic use
  • Dietary Supplements
  • Female
  • Follow-Up Studies
  • HIV
  • HIV Infections* / drug therapy
  • HIV Infections* / etiology
  • HIV Infections* / transmission
  • Humans
  • Infectious Disease Transmission, Vertical
  • Male
  • Parathyroid Hormone / therapeutic use
  • Southeast Asian People
  • Vitamin D
  • Vitamins / therapeutic use
  • Young Adult

Substances

  • Calcium
  • Parathyroid Hormone
  • Procollagen Type I
  • Vitamin D
  • Vitamins